Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

NCT ID: NCT05987332 Phase: PHASE2 / PHASE3 Sponsor: IDEAYA Biosciences Status: Active Not Recruiting

SUMMARY

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

KEY ELIGIBILITY CRITERIA

- * Histological or cytological confirmed Metastatic Uveal Melanoma
- * HLA-A*02:01 negative
- * No prior systemic therapy in the metastatic or advanced setting regional or liver-directed therapy. Ablations or surgical resection of oligometastatic disease, and neoadjuvant or adjuvant therapy is allowed
- * Measurable disease per RECIST 1.1
- * Able to be safely administered and absorb study therapy
- * ECOG performance status 0 or 1
- * Life expectancy of e3 months
- * Adequate organ function
- * Previous treatment with a PKC inhibitor (including prior treatment with IDE196), an inhibitor directly targeting MET, or an inhibitor directly targeting GNAQ/11
- * Concurrent malignant disease

Total sites: 68 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT05987332) and public sources. Generated by FindMyCure.ai.